Ascendis Pharma A/S (asnd 2.25 04/01/28)
13F holders, Q1 2025 (March 31)2holders
1new positions
1sold out
$1.19avg. 13F price*
At the end of Q1 2025, 2 institutions reported holding Ascendis Pharma A/S (asnd 2.25 04/01/28) in their 13F filings, unchanged from Q4 2024. 1 opened new positions and 1 sold out. The largest holders were BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($2.4M) and Bank of New York Mellon Corp ($355K).
- Company
- Ascendis Pharma A/S (asnd 2.25 04/01/28)
- CUSIP
- 04351PAD3
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $355K |
| Exits | 1 | $1.3M |
All 13F filers, Q4 2024 → Q1 2025: 300,000 shares bought and 1,225,001 shares sold, net −925,001 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.01% | Reduce 0.0% | 1,999,999 | $2.4M |
| Bank of New York Mellon Corp | 0.00% | New | 300,000 | $355K |
"% of holder's portfolio" is ASCENDIS PHARMA A/S (ASND 2.25 04/01/28)'s weight in each manager's 13F, not the share of Ascendis Pharma A/S (asnd 2.25 04/01/28) the manager owns.